IDO1 and brain neoplasm: In glioblastoma, diminished therapeutic response to CTLA-4/PD-L1 mAbs in IDO−/− mice compared to WT mice was observed, indicating the requirement for germline IDO to achieve maximal survival benefit from immune checkpoint therapy against brain tumors (196).